Days ahead of Am­gen split, Cy­to­ki­net­ics reads out post-hoc da­ta sug­gest­ing heart drug works bet­ter in sick­er pa­tients — but can the CEO win over skep­tics?

While Cy­to­ki­net­ics’ heart drug tech­ni­cal­ly met its pri­ma­ry end­point back in No­vem­ber, it missed a key sec­ondary end­point — re­duc­tion in car­dio­vas­cu­lar death — which even­tu­al­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER